CLINICAL_TRIALS ClinicalTrials.gov record update

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07491445
Title field or adapter rule: {'original_value': 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:24.256789+00:00
Published At: 2026-10-02T00:00:00+00:00
Record Updated At: 2026-10-02
Source Retrieved At: 2026-10-31T22:17:54.613222+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-02", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07491445"
protocolSection.identificationModule.officialTitle: "RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Arm A: daraxonrasib', 'Arm B: daraxonrasib + gemcitabine and nab-paclitaxel'], 'description': 'oral tablets', 'name': 'daraxonrasib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm B: daraxonrasib + gemcitabine and nab-paclitaxel', 'Arm C: gemcitabine and nab-paclitaxel'], 'description': 'intravenous (IV) infusion', 'name': 'gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm B: daraxonrasib + gemcitabine and nab-paclitaxel', 'Arm C: gemcitabine and nab-paclitaxel'], 'description': 'IV infusion', 'name': 'nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.